Rani Therapeutics Holdings (RANI) Receivables - Accured (2022 - 2023)
Rani Therapeutics Holdings (RANI) posted Receivables - Accured of $200000.0 for Q4 2023, little changed on a QoQ basis from $200000.0 in Q3 2023, and little changed year-over-year from $200000.0 in Q4 2022.
Powered by 
Analysis
Rani Therapeutics Holdings (RANI) Receivables - Accured (2022 - 2023) Analysis & Trends
Rani Therapeutics Holdings has reported Receivables - Accured for 2 years, with the latest figure at $200000.0 in Q4 2023.
- On a quarterly basis, Receivables - Accured changed 0.0% year-over-year to $200000.0 in Q4 2023; TTM through Dec 2023 was $200000.0, a 0.0% change from a year earlier, with the FY2023 full-year figure at $200000.0, changed 0.0% from the prior year.
- Receivables - Accured was $200000.0 for Q4 2023 at Rani Therapeutics Holdings, roughly flat from $200000.0 in the prior quarter.
- The five-year high for Receivables - Accured was $200000.0 in Q4 2022, with the low at $100000.0 in Q1 2023.
Peer Set
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Receivables - Accured (Qtr) |
|---|---|---|---|---|---|
| 1 | Amgen | 203.97 Bn | 189.99 Bn | 7.24 Bn | - |
| 2 | Gilead Sciences | 178.74 Bn | 175.56 Bn | 6.22 Bn | - |
| 3 | Vertex Pharmaceuticals | 130.73 Bn | 122.88 Bn | 2.84 Bn | - |
| 4 | Regeneron Pharmaceuticals | 80.42 Bn | 72.42 Bn | 3.93 Bn | - |
| 5 | Argenx Se | 60.40 Bn | 55.21 Bn | 1.37 Bn | - |
| 6 | Moderna | 57.65 Bn | 52.52 Bn | 52.00 Mn | - |
| 7 | Alnylam Pharmaceuticals | 33.37 Bn | 30.07 Bn | 992.69 Mn | - |
| 8 | Biogen | 32.15 Bn | 30.86 Bn | 1.96 Bn | - |
| 9 | Roivant Sciences | 29.58 Bn | 29.58 Bn | 1.16 Mn | 21.60 Mn |
| 10 | Rani Therapeutics Holdings | 157.97 Mn | 157.97 Mn | - | - |
Historic Data
Download Data
Historic Data
| Date | Value |
|---|---|
| Dec 31, 2023 | 200,000.00 |
| Sep 30, 2023 | 200,000.00 |
| Jun 30, 2023 | 200,000.00 |
| Mar 31, 2023 | 100,000.00 |
| Dec 31, 2022 | 200,000.00 |